Spermidine Decline in Aging Muscle May Drive Sarcopenia
A spatial transcriptomic atlas of aging muscle links falling spermidine levels to muscle wasting, pointing to polyamine metabolism as a therapeutic target.
Summary
Researchers mapped gene activity across different muscle fiber types and tissue compartments in young versus old mice, creating a detailed spatial atlas of how muscles change with age. They found widespread disruptions in muscle fiber structure, energy use, and stress responses. Strikingly, the enzymes that produce polyamines — small molecules including spermidine — were selectively switched off in aged muscle, lowering spermidine levels. When the researchers blocked polyamine production in muscle stem-cell-like cells (fibro-adipogenic progenitors) from both mice and humans, those cells developed hallmarks of aging: excess scar tissue formation, disrupted structural proteins, and a reduced ability to help grow new muscle. A protein called Car3 emerged as a potential blood or tissue biomarker for sarcopenia. The findings suggest that restoring polyamine levels — for example through spermidine supplementation — could be a viable strategy to slow age-related muscle loss.
Detailed Summary
Sarcopenia, the progressive loss of skeletal muscle mass and strength that accelerates after midlife, is a major driver of frailty, falls, and loss of independence in older adults. Understanding its molecular roots is essential for developing effective interventions. This study moves that understanding forward with unprecedented spatial resolution.
Using spatial transcriptomics — a technology that maps gene expression to precise locations within tissue — the Italian and French research team built a comprehensive atlas of skeletal muscle from both young and aged mice. Unlike bulk RNA sequencing, this approach reveals how different fiber types and cellular neighborhoods within muscle are individually affected by aging.
The atlas uncovered broad transcriptional reprogramming across aging muscle: sarcomeric proteins governing contraction were disorganized, excitation-contraction coupling was disrupted, oxidative stress responses were altered, and different fiber types showed distinct metabolic changes. Across multiple muscles and in comparisons with human data, the protein Car3 consistently emerged as a cross-species biomarker candidate for sarcopenia.
The most therapeutically provocative finding was a selective downregulation of polyamine biosynthetic enzymes in aged muscle, resulting in measurably reduced spermidine levels. The research team then tested whether this metabolic decline has functional consequences. By pharmacologically limiting polyamine flux in fibro-adipogenic progenitors (FAPs) — stem-cell-like cells that support muscle regeneration — from both mice and humans, they recapitulated key features of aged muscle: excessive myofibroblast differentiation, extracellular matrix dysregulation, and impaired capacity to support new muscle fiber formation.
These findings position the polyamine pathway as a druggable target for sarcopenia. Spermidine, already available as a dietary supplement and found naturally in foods like wheat germ, has shown promise in aging studies. This mechanistic work provides a cellular rationale for why boosting spermidine in aging muscle might preserve function. Caveats include reliance on mouse models and the absence of intervention data.
Key Findings
- Spatial transcriptomics revealed fiber-type-specific metabolic and structural gene disruptions across aging mouse muscle.
- Polyamine biosynthetic enzymes are selectively downregulated in aged muscle, reducing spermidine levels.
- Blocking polyamine production in human fibro-adipogenic progenitors induces aging-like scar tissue formation and impairs myogenesis.
- Car3 identified as a conserved cross-species biomarker candidate for sarcopenia.
- Polyamine pathway flagged as a promising therapeutic target to slow or reverse muscle aging.
Methodology
The study used spatial transcriptomics to profile skeletal muscle tissue from young and aged mice at single-cell spatial resolution, resolving gene expression by fiber type and tissue compartment. Findings were cross-referenced with human datasets to identify conserved aging signatures. Polyamine pathway function was tested by pharmacologically inhibiting polyamine biosynthesis in both murine and human fibro-adipogenic progenitors in vitro.
Study Limitations
The primary aging model is murine, and while human FAP data were included, direct human muscle aging validation at the spatial transcriptomic level is lacking. No in vivo intervention testing spermidine supplementation or polyamine restoration was performed. This summary is based on the abstract only, so full methodological details, statistical robustness, and supplementary findings cannot be evaluated.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: